Suchergebnisse - "Audigier-Valette, Clarisse"

PubPharm (91)

1

STK11/LKB1 alterations worsen the poor prognosis of KRAS mutated early-stage non-squamous non-small cell lung carcinoma, results based on the phase 2 IFCT TASTE trial

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2024

von Baptiste Oudart, J. | Garinet, S. | Leger, C. | +11

2

Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non-Small-Cell Lung Cancer

enthalten in: Clinical lung cancer | 2023

von Riudavets, M. | Auclin, E. | Mosteiro, M. | +36

3

VEGFR2 and CD34 expression associated with longer survival in patients with pleural mesothelioma in the IFCT-GFPC-0701 MAPS phase 3 trial

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2023

von Levallet, G. | Dubois, F. | Elie, N. | +16

4

RET-MAP : An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET Fusion

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2023

von Aldea, M. | Marinello, A. | Duruisseaux, M. | +42

CommentIn: J Thorac Oncol. 2023 May;18(5):549-551. - PMID 37087114

5

Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2023

von Brahmer, J. | Lee, J. | Ciuleanu, T. | +21

CommentIn: J Clin Oncol. 2023 Feb 20;41(6):1172-1175. - PMID 36623229

6

First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations : CheckMate 817

enthalten in: Journal for immunotherapy of cancer | 2023

von Ready, N. | Audigier-Valette, C. | Goldman, J. | +25

7

Outcome of Patients With Resected Early-Stage Non-small Cell Lung Cancer and EGFR Mutations : Results From the IFCT Biomarkers France Study

enthalten in: Clinical lung cancer | 2023

von Mordant, P. | Brosseau, S. | Milleron, B. | +16

8

Retrospective analysis of real-world data to evaluate actionability of a comprehensive molecular profiling panel in solid tumor tissue samples (REALM study)

enthalten in: PloS one | 2023

von Leroy, K. | Audigier Valette, C. | Alexandre, J. | +16

9

Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC : A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2023

von Paz-Ares, L. | Ciuleanu, T. | Pluzanski, A. | +25

CommentIn: J Thorac Oncol. 2023 Jan;18(1):10-13. - PMID 36543429

10

Effectiveness of Nivolumab in Second-Line and Later in Patients with Advanced Non-Small Cell Lung Cancer in Real-Life Practice in France and Germany : Analysis of the ESME-AMLC and CRISP Cohorts

enthalten in: Cancers | 2022

von Chouaid, C. | Thomas, M. | Debieuvre, D. | +15

1
2
3
4
5
6
7
8
9
10
Nächster »
[10]